Next 10 |
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 09:00:01 ET Read the full article on Seeking Alpha For further details see: UroGen Pharma stock slumps after pricing stock and warrants offering
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
2024-06-17 17:10:59 ET More on UroGen Pharma UroGen: Q3 NDA Opens Hefty Revenue Opportunity UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript UroGen surges on updated late-stage data for bladder cancer therapy Urogen files patent suit against Teva ov...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...
2024-06-17 09:00:00 ET Summary ENVISION DOR data released in Q2, 2024 showed an unprecedented 82.3% Duration of Response for UGN-102. Following such positive data, it expects to make an FDA submission late in Q3, 2024, with potential for priority review. UroGen Pharma's blockb...
2024-06-14 09:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for URGN on June 14, 2024 07:43AM ET. The previous analyst recommendation was Outperform. URGN was trading at $17.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-06-14 09:00:10 ET Leland Gershell from Oppenheimer issued a price target of $40.00 for URGN on 2024-06-14 07:43:00. The adjusted price target was set to $40.00. At the time of the announcement, URGN was trading at $17.5. The overall price target consensus is at $38....
2024-06-14 07:15:04 ET Goldman Sachs analyst issues NEUTRAL recommendation for URGN on June 14, 2024 05:11AM ET. The previous analyst recommendation was Neutral. URGN was trading at $17.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...